P526: REAL-WORLD COMPARISON OF DIFFERENT TREATMENT MODALITIES FOR FAVORABLE RISK ACUTE MYELOID LEUKEMIA: STANDARD DOSE ANTHRACYCLINE VS HIGH DOSE ANTHRACYCLINE VS ADDITION OF GEMTUZUMAB OZOGAMICIN. (23rd June 2022)

• Record Type: Journal Article
• Authors: Mort, J.; Brewer, B.; Mautner, B.; Dibenedetto, S.; Pierce, E.; Morse, E.; Wells, L.; Ghamsari, F.; Morris, A.; Clark, S.; Reid, J.; Patel, I.; Jackson, C.; Perciavalle, M.; Yelvington, B.; Miller, R.; Abernathy, K.; Wolfe, H.; Locke, S.; Zeidner, J.; Reed, D.; Duong, V.; Dholaria, B.; LeBlanc, T.; Keng, M.; Horton, B.; El Chaer, F.
• Is Part Of: HemaSphere. Volume 6(2022)Supplement 3
• Page Start: 425
• Page End: 426
• Publication Date: 2022-06-23
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1097/01.HS9.0000844992.77306.44
• Languages: English
• ISSNs: 2572-9241